Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review

The role of conventional radiotherapy in the management of pancreatic cancer has yet to be elucidated. Over the past decade, stereotactic body radiotherapy (SBRT) has emerged as a novel therapeutic option in pancreatic cancer care. This study evaluated the survival impact of SBRT on patients with unresected pancreatic cancer.

[1]  C. Ko,et al.  The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States , 2008, Annals of Surgical Oncology.

[2]  W. Fulp,et al.  A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer , 2015, Journal of Gastrointestinal Cancer.

[3]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[4]  Daniel T Chang,et al.  Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas , 2009, Cancer.

[5]  M. Büchler,et al.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.

[6]  W. Chu,et al.  Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[7]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[8]  T. Desser,et al.  Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.

[9]  M. Javle,et al.  Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  Rebecca Slack,et al.  Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety , 2013, Radiation oncology.

[11]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[12]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[13]  E. Nakakura,et al.  Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  Arsh K Jain,et al.  The secret of immortal time bias in epidemiologic studies. , 2008, Journal of the American Society of Nephrology : JASN.

[15]  J. Massagué,et al.  Smad4/DPC4 Silencing and Hyperactive Ras Jointly Disrupt Transforming Growth Factor-β Antiproliferative Responses in Colon Cancer Cells* , 1999, The Journal of Biological Chemistry.

[16]  Q. Yao,et al.  Overcoming drug resistance in pancreatic cancer , 2011, Expert opinion on therapeutic targets.

[17]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[19]  D. Tait,et al.  Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy , 2007, British Journal of Cancer.

[20]  Dwight E Heron,et al.  Stereotactic Body Radiotherapy in the Treatment of Advanced Adenocarcinoma of the Pancreas , 2011, American journal of clinical oncology.

[21]  Chad A. LaGrange,et al.  NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[23]  J. Marshall,et al.  Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma , 2014, American journal of clinical oncology.

[24]  Albert C Koong,et al.  Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. , 2004, International journal of radiation oncology, biology, physics.

[25]  Anca-Ligia Grosu,et al.  Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer - a systematic review. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  Julian A. Kim,et al.  Surgery for Localized Pancreatic Cancer: The Trend Is Not Improving , 2016, Pancreas.

[27]  David Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[28]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 1.2019. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[29]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[30]  B. Chauffert,et al.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Cameron,et al.  The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience , 2015, Annals of Surgical Oncology.

[32]  H. Nava,et al.  Radiation therapy combined with adriamycin or 5‐fluorouracil for the treatment of locally unresectable pancreatic carcinoma , 1985, Cancer.

[33]  Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. , 1988, Journal of the National Cancer Institute.

[34]  Jan van der Meulen,et al.  Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. , 2006, Journal of clinical epidemiology.